AAFA Meets Asthma and Allergy Awareness Month with 31 DAYS OF ACTION
April 29, 2021 14:03 ET | Asthma and Allergy Foundation of America
Washington, D.C, April 29, 2021 (GLOBE NEWSWIRE) -- May is National Asthma and Allergy Awareness Month. This year the Asthma and Allergy Foundation of America (AAFA) is encouraging everyone to look...
AAFA Celebrates Massive Health Policy Change; Lawmakers Pass FASTER Act Making Sesame A Major Food Allergen
April 14, 2021 17:55 ET | Asthma and Allergy Foundation of America
Washington, D.C., April 14, 2021 (GLOBE NEWSWIRE) -- Today the House passed Act, S. 578/H.R.1202, otherwise known as the FASTER Act. It declares sesame the 9th major food allergen recognized by law...
intrommune_icon_500x500.png
Intrommune Therapeutics Names Chief Operating Officer
March 25, 2021 09:10 ET | Intrommune Therapeutics
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
intrommune_icon_500x500.png
Research Presentations at the 2021 Annual AAAAI Meeting Highlight Limitations of Current Food Allergy Treatments and Further Validates Intrommune Therapeutics’ Approach
March 12, 2021 09:30 ET | Intrommune Therapeutics
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- The clinical and scientific team of Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing patient-friendly treatments...
intrommune_icon_500x500.png
Intrommune Therapeutics Publishes Peanut Allergy and Immunotherapy Report
February 23, 2021 12:00 ET | Intrommune Therapeutics
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly immunotherapy platform for the treatment of...
intrommune_icon_500x500.png
Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301
February 04, 2021 09:13 ET | Intrommune Therapeutics
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
Intrommune Logo Only - 250k.jpg
Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021”
January 07, 2021 17:35 ET | Intrommune Therapeutics
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will...
It’s OFFICIAL: Huge AAFA Advocacy Victory! School-Based Allergies and Asthma Management Program Act, H.R. 2468 Becomes Law
January 05, 2021 18:59 ET | Asthma and Allergy Foundation of America
Washington D.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Today the president signed H.R. 2468, the School-Based Allergies and Asthma Management Program Act into law. This bipartisan legislation will help...
AAFA Celebrates Major Advocacy Win! Congress Passes School-Based Allergies and Asthma Management Program Act, H.R. 2468
December 17, 2020 19:13 ET | Asthma and Allergy Foundation of America
Washington D.C., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Today Congress passed H.R. 2468, the School-Based Allergies and Asthma Management Program Act. This bipartisan bill will help millions of U.S....
AAFA Praises U.S. House Passage of the FASTER Act
November 17, 2020 21:34 ET | Asthma and Allergy Foundation of America
Washington D.C., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Today the House of Representatives passed H.R. 2117. Named the Food Allergy Safety, Treatment, and Research Act, it is easier known as the FASTER...